Evidence map›Paper›PMID 34883551›Full record

ArticleThe Korean journal of internal medicine2022

Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis.

Kichul Shin, Hyun Mi Kwon, Min Jung Kim, Myung Jae Yoon, Hyun Gyung Chai, Seong-Wook Kang, Won Park, Sung-Hwan Park, Chang Hee Suh, Hyun Ah Kim and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kichul ShinDivision of Rheumatology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
Hyun Mi KwonDivision of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Min Jung KimDivision of Rheumatology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
Myung Jae YoonDivision of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Hyun Gyung ChaiDivision of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Seong-Wook KangDivision of Rheumatology, Chungnam National University Hospital, Daejeon, Korea.
Won ParkDivision of Rheumatology, Inha University Hospital, Incheon, Korea.
Sung-Hwan ParkDivision of Rheumatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chang Hee SuhDivision of Rheumatology, Ajou University Hospital, Suwon, Korea.
Hyun Ah KimDivision of Rheumatology, Hallym University Sacred Heart Hospital, Anyang, Korea.
Seung-Geun LeeDivision of Rheumatology, Pusan National University Hospital, Busan, Korea.
Choong Ki LeeDivision of Rheumatology, Yeungnam University Medical Center, Daegu, Korea.
Sang-Cheol BaeDivision of Rheumatology, Hanyang University Seoul Hospital, Seoul, Korea.
Yong-Beom ParkDivision of Rheumatology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Yeong Wook SongDivision of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe aim of this study was to investigate long-term post-discontinuation outcomes in patients with rheumatoid arthritis (RA) who had been treated with tumor necrosis factor-α inhibitors (TNF-αi) which was then discontinued.

methodsSixty Korean patients with RA who participated in a 5-year GO-BEFORE and GO-FORWARD extension trials were included in this retrospective study. Golimumab was deliberately discontinued after the extension study (baseline). Patients were then followed by their rheumatologists. We reviewed their medical records for 2 years (max 28 months) following golimumab discontinuation. Patients were divided into a maintained benefit (MB) group and a loss-of-benefit (LB) group based on treatment pattern after golimumab discontinuation. The LB group included patients whose conventional disease-modifying antirheumatic drug(s) were stepped-up or added/switched (SC) and those who restarted biologic therapy (RB).

resultsThe mean age of patients at baseline was 56.5 years and 55 (91.7%) were females. At the end of follow-up, 23 (38.3%) patients remained in the MB group. In the LB group, 75.7% and 24.3% were assigned into SC and RB subgroups, respectively. Fifty percent of patients lost MB after 23.3 months. Demographics and clinical variables at baseline were comparable between MB and LB groups except for age, C-reactive protein level, and corticosteroid use. Restarting biologic therapy was associated with swollen joint count (adjusted hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.01 to 3.55) and disease duration (adjusted HR, 1.12; 95% CI, 1.02 to 1.23) at baseline.

conclusionTreatment strategies after discontinuing TNF-αi are needed to better maintain disease control and quality of life of patients with RA.

Indexed as

Antibodies, MonoclonalArthritis, RheumatoidWithholding TreatmentAntirheumatic AgentsFemaleHumansImmunologic FactorsMaleMiddle AgedQuality of LifeRepublic of KoreaRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalAntirheumatic AgentsgolimumabImmunologic FactorsAntirheumatic agentsArthritis, rheumatoidBiological therapyGolimumab

Identifiers

PMID34883551
PMCPMC9449209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.